Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Guided Posters

Thyroid Nodules and Cancer

ea0063gp82 | Thyroid Nodules and Cancer | ECE2019

Coexistence of the BRAF V600E and TERT promoter mutations and their impact on response to therapy and final outcome of papillary thyroid cancer

Trybek Tomasz , Walczyk Agnieszka , Gęsior-Perczak Danuta , Pałyga Iwona , Mikina Estera , Kowalik Artur , Kopczyński Janusz , Chrapek Magdalena , Goźdź Stanisław , Kowalska Aldona

Introduction: Coexistence of the BRAF V600E and TERT promoter mutations may correlate with more aggressive histopathological features and worse course of the disease. According to the American Thyroid Association (ATA) dynamic risk stratification with modified initial estimated risk based on response- to-therapy and disease course allows individual risk assessment and support clinicians in the appropriate management approach to differentiated thyroid cancer (...

ea0063gp83 | Thyroid Nodules and Cancer | ECE2019

Prognostic significance of TERT promoter and BRAF mutations in cytologically suspicious or malignant thyroid nodules: a monocentric case series at a tertiary-level endocrinology unit

Censi Simona , Barollo Susi , Grespan Elisabetta , Watutantrige-Fernando Sara , Cavedon Elisabetta , Manso Jacopo , Iacobone Maurizio , Ide Eric Casal , Galuppini Francesca , Fassina Ambrogio , Pennelli Gianmaria , Vianello Federica , Bertazza Loris , Mian Caterina

Background: Follicular-derived thyroid cancers (FDTC) generally have a good prognosis. Nonetheless, a minority of them have an aggressive behavior and develop distant metastases, with increased mortality rates. Pre-surgically available prognostic markers, able to identify this group of patients are still lacking.Materials and methods: The study involved 436 FNA samples with a malignant/suspicious cytology obtained from thyroid nodules in 436 consecutive ...

ea0063gp84 | Thyroid Nodules and Cancer | ECE2019

Polygenic susceptibility to papillary thyroid cancer: detection of the main genetic signature in Italian patients

Brigante Giulia , Lazzaretti Clara , Paradiso Elia , Foersti Asta , Hemminki Kari , Elisei Rossella , Romei Cristina , Simoni Manuela , Landi Stefano , Casarini Livio

Introduction and aim: Thyroid cancer is the most common endocrine neoplasia affecting 0.2–1.5% of the individuals worldwide and its incidence is increasing [1]. Papillary thyroid carcinoma (PTC) is the main histotype (80–90%). PTC susceptibility is the result of genetic predisposition, environmental factors and lifestyle. We hypothesized that genetic predisposition to PTC is poligenic and characterized by a genetic signature involving combinations of genes previously...

ea0063gp85 | Thyroid Nodules and Cancer | ECE2019

Follistain-like 1 (Fstl1) may reduce metastastic activity of anaplastic thyroid cancer by increasging thyroid transcription factor 1 (TTF1) and epithelial gene markers

Park Jong Suk , Choi Arim , Kim Jung Hye , Park Kahui , Lee Sang Bae , Kim YuSik , Nam Ji Sun , Kang Shinae , Ahn Chul Woo

Background: Although anaplastic thyroid cancer (ATC) is found in less than 2% of patients with thyroid cancer, it is the most advanced, aggressive and lethal. ATC is known to develop from well-differentiated thyroid cancers, such as follicular thyroid cancer, and it is undifferentiated itself. Among the thyroid-specific transcription factors that are critical for the function of thyroid, the expression of thyroid transcription factor 1 (TTF1), or NKX2.1, has been reported to c...

ea0063gp86 | Thyroid Nodules and Cancer | ECE2019

Benefits and limitations of TKIs in patients with medullary thyroid cancer: a systematic review and meta-analysis

Efstathiadou Zoe , Tsentidis Charalambos , Bargiota Alexandra , Daraki Vasiliki , Kotsa Kalliopi , Ntali Georgia , Papanastasiou Lamprini , Tigas Stylianos , Toulis Konstantinos , Pazaitou-Panayiotou Kalliopi , Alevizaki Maria

Tyrosine Kinase Inhibitors (TKIs) have been used in patients with advanced Medullary Thyroid Carcinoma (MTC). However, for some compounds, data on effectiveness and safety are limited. The aim of this systematic review and meta-analysis was to document clinical response and toxicities of TKIs in advanced MTC.Methods: A literature search in MEDLINE, EMBASE and Cochrane until May 2018 was performed for articles or abstracts on TKI use in MTC. Studies were ...

ea0063gp87 | Thyroid Nodules and Cancer | ECE2019

Intronic RAS and PI3KCA mutations identified by Next Generation Sequencing in thyroid nodules with indeterminate cytology may associate with follicular thyroid cancer

Borges de Souza Patricia , Rossi Lucrezia , Crociara Anna , Rossi Roberta , Ambrosio Maria Rosaria , Rossi Martina , Bondanelli Marta , Lanza Giovanni , Zatelli Maria Chiara

Introduction: Accurately discern malignant from benign nodules sometimes represents a real challenge. Fine needle aspiration (FNA) biopsy, ultrasound and The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) allow for accurate diagnosis in 60–80% of all nodules. However, 10–20% of thyroid FNAs yield an indeterminate cytology (BSRTC III and IV categories). The real malignancy rate of BSRTC III category is difficult to ascertain because histopathological anal...

ea0063gp88 | Thyroid Nodules and Cancer | ECE2019

An analysis of false-positive uptake on radioiodine whole-body scintigraphy

Iyidir Ozlem Turhan , Buyukaşık Pırıl , Mwinyi Adam Rajab , Aktas Ayse , Gencoglu Arzu , Tutuncu Neslihan Bascil

Introduction: Radioiodine can be used for the ablation/treatment and imaging of thyroid cancer. However, radioiodine uptake is not specific for thyroid tissue. Iodine-131 can show physiologic accumulation in several organs as breast, thymus, liver and gastrointestinal tract, or in benign conditions, such as cysts and inflammation, or in a variety of benign and malignant non-thyroidal tumors, which could be mistaken for thyroid cancer or cancer metastasis. Here we aimed to eval...

ea0063gp89 | Thyroid Nodules and Cancer | ECE2019

Prospective sonographic assessment of 214 consecutive nodules as per the ATA 2015 guidelines. Real world data

Kyriacou Angelos , Zavros Giorgos

Introduction: Most studies which scrutinized the ATA 2015 thyroid nodule guidelines were performed retrospectively, in tertiary centers of excellence and in Western populations. We sought to prospectively apply these guidelines, under ‘real world’ conditions and in an eastern Mediterranean population.Methods: Thyroid nodules were prospectively and independently assessed by two experienced sonographers and classified as per the guidelines. Only ...

ea0063gp90 | Thyroid Nodules and Cancer | ECE2019

Treatment modalities in DTC patients with neck disease persistence. Second surgical intervention is more beneficial than only radioiodine (RAI) treatment

Saltiki Katerina , Simeakis George , Konstantakatou Panagiota , Sapounas Spyros , Alevizaki Maria

Objectives: DTC has a favorable clinical course. A small percentage of patients undergoing surgery and RAI ablation may have local disease persistence and further therapeutic interventions may be needed such as further RAI administration following or not a second surgery. We investigated whether additional therapeutic interventions may be beneficial for the clinical course in DTC patients with disease persistence.Methods: 812 DTC patients (men 25.7%, age...

ea0063gp91 | Thyroid Nodules and Cancer | ECE2019

Detection of EIF1AX, CHEK2 and PPM1D gene variants in thyroid carcinomas

Dvorakova Sarka , Pekova Barbora , Sykorova Vlasta , Vacinova Gabriela , Vaclavikova Eliska , Moravcova Jitka , Katra Rami , Vlcek Petr , Sykorova Pavla , Plzak Jan , Bavor Petr , Kodetova Daniela , Chovanec Martin , Vcelak Josef , Bendlova Bela

Objectives: The identification of novel causing genes in thyroid carcinoma is very important in diagnosis and prognosis of the disease. Recently, The Cancer Genome Atlas (TCGA) study found EIF1AX, CHEK2 and PPM1D genes as new minor causing genes in the papillary thyroid cancer (PTC) development. The goal of this study was to detect variants in these genes in PTC, follicular thyroid carcinoma (FTC) and anaplastic thyroid carcinoma (ATC) cohorts.<p class="a...

ea0063gp92 | Thyroid Nodules and Cancer | ECE2019

Diagnostic performance evaluation of a computer-assisted imaging analysis system for ultrasound risk stratification of thyroid nodules

L Reverter Jordi , Puig-Jove Carlos , Vazquez Federico , Puig-Domingo Manel

Aim: To evaluate the diagnostic effectiveness of the first commercially available computer-aided diagnostic (CAD) imaging analysis system.Methods: Ultrasound images of 300 thyroid nodules (135 malignant) acquired prior to surgical treatment were retrospectively reviewed by a thyroid expert, and then the classification of each image was compared to the classification rendered by an image analysis program (AmCAD-UT®). The American Thyroid A...

ea0063gp93 | Thyroid Nodules and Cancer | ECE2019

Tirads classification and final diagnosis of thyroid nodules classified as bethesda-3 after fine-needle aspiration

Rosa Alhambra Exposito Maria , Barrera Martin Ana , Segui Azpilcueta Pedro , Angeles Galvez Moreno Maria

Introduction: Ultrasound is the main diagnostic tool for imaging pathology of the thyroid gland. The TI-RADS classification allows the evaluation of a risk of malignancy in the case of thyroid nodules, indicating the need to perform a puncture for a histological study. Bethesda system classifies them according to the cytological malignancy risk. Bethesda category 3 (B3) comprises ‘follicular lesion of undetermined significance’ or ‘atypia of undetermined signifi...